LFSC
F/m Emerald Life Sciences Innovation ETF
Price Chart
Latest Quote
$43.12
+1.14 (+2.71%)
Current Price
| Previous Close | $41.98 |
| Open | $42.30 |
| Day High | $43.12 |
| Day Low | $42.30 |
| Volume | 2,803 |
Fund Information
| Net Assets | $123.35M |
| Expense Ratio | 0.54% |
| Category | Health |
| Fund Family | Emerald Mutual Fund Advisers Trust |
| Net Asset Value | $42.12 |
| Premium/Discount | 2.37% |
| Exchange | NGM |
📊 ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $42.20 |
| SMA50 | $44.51 |
| SMA200 | $40.47 |
| RSI | 56.07 |
| ATR | 0.9556 |
| Rel Volume | 0.82 |
Performance History
| Week | +1.72% |
| Month | -3.21% |
| Quarter | -4.04% |
| 6 Months | +16.61% |
| YTD | +19.04% |
| Year | +39.54% |
| 10 Years | +73.23% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $43.12 | 2,803 |
| 2026-10-26 | $42.10 | 1,900 |
| 2026-10-23 | $41.59 | 800 |
| 2026-10-22 | $42.58 | 20,600 |
| 2026-10-21 | $42.61 | 3,700 |
| 2026-10-20 | $42.39 | 12,500 |
| 2026-10-19 | $40.91 | 1,700 |
| 2026-10-16 | $39.92 | 5,600 |
| 2026-10-15 | $41.51 | 1,400 |
| 2026-10-14 | $40.75 | 1,600 |
| 2026-10-13 | $40.95 | 1,600 |
| 2026-10-12 | $42.03 | 1,100 |
| 2026-10-09 | $42.61 | 600 |
| 2026-10-08 | $41.67 | 1,900 |
| 2026-10-07 | $41.84 | 500 |
| 2026-10-06 | $42.11 | 2,400 |
| 2026-10-05 | $43.94 | 600 |
| 2026-10-02 | $43.40 | 2,400 |
| 2026-10-01 | $43.46 | 1,200 |
| 2026-09-30 | $44.57 | 3,600 |
| 2026-09-29 | $44.33 | 1,600 |
| 2026-09-28 | $44.54 | 800 |
About F/m Emerald Life Sciences Innovation ETF
The fund is an actively managed exchange-traded fund (“ETF”) and invests primarily in equity securities of life science companies selected by Emerald Mutual Fund Advisers Trust, the fund’s investment sub-adviser, under the supervision of the adviser. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities issued by life science companies demonstrating innovation.
📰 Latest News
No news articles available at the moment. Check back later for updates on LFSC.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.